Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,288 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastro-Intestinal Cancer Clear all

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Los Angeles, California • Nashville, Tennessee + 2 more

Conditions: Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions: Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery; Procedure · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Colorectal Cancer, Precancerous Condition
Interventions: celecoxib, placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years to 14 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Interventions: HyperSight Imaging; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer
Interventions: favezelimab/pembrolizumab, regorafenib, TAS-102; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions: LMB-9 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
Interventions: Semi Quantitative Food Frequency Questionnaire (SQFFQ); Behavioral
Lead sponsor: San Raffaele University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2035
U.S. locations: 2
States / cities: Denver, Colorado • Chicago, Illinois

Conditions: Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions: Carfilzomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postoperative Ileus, Colon Cancer, Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions: Acupuncture, Sham Acupuncture; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Cachexia, Weight Loss, Gastrointestinal Cancer
Interventions: EXCAP©®; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Fort Myers, Florida • Chicago, Illinois • Goshen, Indiana + 7 more

Conditions: Colon Adenocarcinoma
Interventions: Carbon C 14 Oxaliplatin, Oxaliplatin; Drug
Lead sponsor: Edward Kim; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metastatic Gastric Cancer, Locally Advanced Gastric Cancer
Interventions: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly; Drug
Lead sponsor: Huashan Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: ALX2004; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: La Jolla, California • Santa Monica, California • Tampa, Florida + 9 more

Conditions: Neoplasm Metastasis, Colorectal Neoplasms
Interventions: Celecoxib, Irinotecan, 5-fluorouracil, Leucovorin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 12
States / cities: Mobile, Alabama • Fort Lauderdale, Florida • Port Saint Lucie, Florida + 9 more

Conditions: Insomnia
Interventions: CBT, MBSR; Behavioral
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 2
States / cities: Camden, New Jersey • Voorhees Township, New Jersey

Conditions: Colorectal Cancer Screening
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Gastric Adenocarcinoma
Interventions: Paclitaxel, Olaparib, Pembrolizumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions: Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 39 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Colorectal Cancer
Interventions: automated telephone reminder, prevention coordinator, Health literacy appropriate education and demonstration; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 50 Years to 75 Years
Enrollment: 620 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
Interventions: PF-07062119, Anti-PD1, Anti-VEGF; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 6 more

Search by objective public record fields.

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Evaluation of Improved Onboard Patient Imaging

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Trial of Acupuncture for Reduction of Post-Colectomy Ileus

Pancreas Registry and High Risk Registry

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

Metronomic Chemotherapy in Advanced Gastric Cancer

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

Insomnia Interventions in Cancer Survivors

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

FITting Non-invasive Tests in Lynch Syndrome Surveillance

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Health Literacy Interventions to Overcome Disparities in CRC Screening

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.